Junli Deng

Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression

Junli Deng, Xupeng Bai, Xiaojie Feng et al. · BMC Cancer · 2019 · 231 citations · Full text

Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy

Jingli Hao, Peter Graham, Lei Chang et al. · Oncotarget · 2016 · 31 citations · Full text

Tumor Biology, Radiation Medicine, Oncology +15

Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients

Junli Deng, Junli Deng, Daohua Shi et al. · Clinical & Translational Oncology · 2015 · 23 citations

Cisplatin-based Chemotherapy, Medicine, Pathology +9

LFNAT 2023 Challenge on Light Field Depth Estimation: Methods and Results

Hao Sheng, Yebin Liu, Jingyi Yu et al. · 2023 · 13 citations

Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy

Junli Deng, Li Wang, Jie Ni et al. · Expert Review of Proteomics · 2016 · 10 citations

Proteomic Technology, Medicine, Biomarker Target +9